News and Announcements
INOPTEC delivered 400% ROI
- Published April 21, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
The “Innovator of the Year” awarded INOPTEC has just raised 250k EUR from a strategic plastic part supplier this week, on top of the 1 Mio. EUR which was already raised.
INOPTEC has developed and patented the world’s first Vision Enhancement System (VES), which comprises smart glasses and LED lamps, enabling instant light adaptation & protection – day or night – to improve the wearer’s safety and performance under otherwise impossible and dangerous viewing/light conditions!
UK Policy:
PA Consulting Group (R&D firm Cambridge) and Kinnier Dufort (Design firm Bristol) are still set as top-notch development partners for the British-German high-tech start-up INOPTEC Ltd. – even after Brexit, says the founder and CEO, Ralf G.J. Knoll.
We can maximise our R&D and marketing abilities by combining our UK tech clusters with those in Germany, Ireland and the US.
And with 80 patents underway – we can create a worldwide monopoly!
Smart glass users can go beyond themselves – and become unstoppable!
Company Updates
The RBA Just Validated the Shift to Private Credit
With the RBA’s latest decision confirming the ‘higher for longer’ environment, sophisticated investors are rotating capital from rate-sensitive public markets into private credit for superior, lower-volatility yields. The era of cheap money is over, making private credit a necessary multi-year positioning decision.
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Backed By Leading Investment Groups and Family Offices
